共 50 条
- [1] The phase 3 INTerpath-002 study design: Individualized neoantigen therapy (INT) V940 (mRNA-4157) plus pembrolizumab vs placebo plus pembrolizumab for resected early-stage non-small-cell lung cancer (NSCLC)CANCER RESEARCH, 2024, 84 (07)Spicer, Jonathan D.Nair, Santosh M.Khattak, AdnanLee, Jay M.Brown, MichelleMeehan, Robert S.Shariati, NazlyDeng, XuanSamkari, AymanChaft, Jamie E.
- [2] mRNA-4157 (V940) individualized neoantigen therapy plus pembrolizumab vs pembrolizumab in high-risk resected melanoma: Clinical efficacy and correlates of responseANNALS OF ONCOLOGY, 2023, 34 : S1288 - S1289Weber, J. S.Khattak, A.Carlino, M.Sullivan, R. J.Luke, J. J.Meniawy, T.Taylor, M.Ansstas, G.Kim, K.Mckean, M.Faries, M.Tran, T.Cowey, C. L.Pecora, A.Medina, T.Atkinson, V. G.Gibney, G.Buchbinder, E.Meehan, R.Long, G. V.
- [3] Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b studyLANCET, 2024, 403 (10427): : 632 - 644Weber, Jeffrey S.Carlino, Matteo S.Khattak, AdnanMeniawy, TarekAnsstas, GeorgeTaylor, Matthew H.Kim, Kevin B.McKean, MeredithLong, Georgina, VSullivan, Ryan J.Faries, MarkTran, Thuy T.Cowey, C. LancePecora, AndrewShaheen, MontaserSegar, JenniferMedina, TheresaAtkinson, VictoriaGibney, Geoffrey T.Luke, Jason J.Thomas, SajeveBuchbinder, Elizabeth, IHealy, Jane A.Huang, MoMorrissey, ManjuFeldman, IgorSehgal, VasudhaRobert-Tissot, CelineHou, PeijieZhu, LiliBrown, MichelleAanur, PraveenMeehan, Robert S.Zaks, Tal
- [4] Individualized neoantigen therapy mRNA-4157 (V940) plus pembrolizumab in resected melanoma: 3-year update from the mRNA-4157-P201 (KEYNOTE-942) trial.JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (17_SUPPL) : LBA9512 - LBA9512Weber, Jeffrey S.Khattak, Muhammad AdnanCarlino, Matteo S.Meniawy, TarekTaylor, Matthew H.Ansstas, GeorgeKim, Kevin B.McKean, MeredithSullivan, Ryan J.Faries, Mark B.Tran, ThuyCowey, Charles LanceMedina, TheresaSegar, Jennifer MargaretAtkinson, VictoriaGibney, Geoffrey ThomasLuke, Jason J.Buchbinder, Elizabeth IannottiLong, Georgina V.Meehan, Robert S.
- [5] mRNA-4157 (V940) individualized neoantigen therapy (INT) plus pembrolizumab (pembro) in advanced unresectable HPV- head & neck carcinoma (HNSCC): Clinical & translational analysisCANCER RESEARCH, 2024, 84 (07)Bauman, Julie E.Julian, Ricklie A.Geiger, Jessica L.Mehnert, Janice M.Clarke, Jeffrey M.Patel, Manish R.Gutierrez, MartinGainor, Justin F.Srivats, ShyamZhang, ZhaojieRao, AnjaliSehgal, VasudhaHou, PeijieMorrissey, ManjuFeldman, IgorSrinivasan, LakshmiAanur, PraveenBrown, MichelleMeehan, Robert S.
- [6] INTerpath-004: A phase 2, randomized, double-blind study of pembrolizumab with V940 (mRNA-4157) or placebo in the adjuvant treatment of renal cell carcinomaONCOLOGIST, 2024, 29 : S16 - S16Jang, AlbertMargevicius, SeungheeFu, PingfuZhong, JeffreyKumar, HamsaCalaway, AdamShoag, JonathanBukavina, LauraJia, AngelaMendiratta, PrateekRao, SantoshSheng, IrisBrown, JasonGarcia, JorgeBarata, Pedro
- [7] Overall survival in the KEYNOTE-671 study of perioperative pembrolizumab for early-stage non-small-cell lung cancer NSCLC)ANNALS OF ONCOLOGY, 2023, 34 : S1297 - S1298Spicer, J. D.Gao, S.Liberman, M.Kato, T.Tsuboi, M.Lee, S. H.Chen, K. N.Dooms, C.Majem, M.Eigendorff, E.Martinengo, G.Bylicki, O.Garassino, M. C.Abreu, D. RodriguezChaft, J.Novello, S.Yang, J.Keller, S. M.Samkari, A.Wakelee, H.
- [8] Phase III study of selpercatinib vs chemotherapy plus /- pembrolizumab in untreated RET positive non-small-cell lung cancerFUTURE ONCOLOGY, 2021, 17 (07) : 763 - 773Solomon, Benjamin J.Zhou, Cai CunDrilon, AlexanderPark, KeunchilWolf, JurgenElamin, YasirDavis, Hannah M.Soldatenkova, VictoriaSashegyi, AndreasLin, Aimee BenceLin, Boris K.Loong, Herbert H.Novello, SilviaArriola, EdurnePerol, MauriceGoto, KoichiSantini, Fernando C.
- [9] Phase 3 study of neoadjuvant pembrolizumab or placebo plus chemotherapy, followed by adjuvant pembrolizumab or placebo plus endocrine therapy for early-stage high-risk ER+HER2-breast cancer :KEYNOTE-756ANNALS OF SURGICAL ONCOLOGY, 2024, 31 (01) : S4 - S5Cardoso, FatimaO'Shaughnessy, JoyceMcArthur, HeatherSchmid, PeterCortes, JavierHarheck, NadiaTelli, Melinda L.Cescon, David W.Fasching, Peter A.Shao, ZhiminLoirat, DelphinePark, Yeon HeeGonzalez Fernandez, ManuelRubovszky, GaborIm, Seock-AhHui, RinaTakano, ToshimiAndre, FabriceYasojima, HiroyukiLiu, Zhenzhen
- [10] Phase 3 study of neoadjuvant pembrolizumab or placebo plus chemotherapy, followed by adjuvant pembrolizumab or placebo plus endocrine therapy for early-stage high-risk ER+/ HER2-breast cancer: KEYNOTE-756CANCER RESEARCH, 2024, 84 (09)Cardoso, FatimaO'Shaughnessy, JoyceMcArthur, HeatherSchmid, PeterCortes, JavierHarbeck, NadiaTelli, MelindaCescon, DavidFasching, Peter A.Shao, ZhiminLoirat, DelphinePark, Yeon HeeFernandez, Manuel GonzalezRubovszky, GaborIm, Seock-AhHui, RinaTakano, ToshimiAndre, FabriceYasojima, HiroyukiLiu, ZhenzhenDing, YuJia, LiyiKarantza, VassilikiTryfonidis, KonstantinosBardia, Aditya